From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Ana Flávia Mendes Batista und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms, Cytochrome P-450 CYP2D6, Drug Monitoring. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal em Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Endoxifen is the most active metabolite of tamoxifen and plays a central role in its therapeutic efficacy. However, significant interindividual variability in endoxifen plasma concentrations, driven by both genetic and non‐genetic factors, may result in subtherapeutic exposure for a substantial subset of patients. This study evaluated the influence of CYP2D6 phenotype and age on endoxifen steady‐state concentrations and explored the clinical utility of therapeutic drug monitoring (TDM) to guide tamoxifen therapy. A total of 63 breast cancer patients receiving tamoxifen 20 mg daily for at least 3 months were enrolled. Patients were genotyped for CYP2D6 using TaqMan assays and classified as normal metabolizers (NMs, n = 49), intermediate metabolizers (IMs, n = 13), or ultrarapid metabolizers (UMs, n = 1). Plasma concentrations of tamoxifen and its metabolites were quantified by LC‐MS/MS at steady state. Endoxifen levels were significantly lower in IMs (7.13 ng/mL; 95% CI: 3.38‐15.08) compared to NMs (22.66 ng/mL; 95% CI: 18.57‐27.66; P < .001). Subtherapeutic endoxifen concentrations (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
- Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
ORCID-Profile: Letícia Penteado Petrolli, Vera Lucia Lanchote, João Paulo Bianchi Ximenez
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal em Nível Superior
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Mendes Batista, A. F., Petrolli, L. P., Marques Pereira, M. P., Rocha, A., Moreira de Andrade, J., Lanchote, V. L., & Bianchi Ximenez, J. P. (2025). From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70103
Vancouver
Mendes Batista AF, Petrolli LP, Marques Pereira MP, Rocha A, Moreira de Andrade J, Lanchote VL, et al. From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70103
BibTeX
@article{MendesBatista2025,
author = {Mendes Batista, Ana Flávia and Petrolli, Letícia Penteado and Marques Pereira, Maria Paula and Rocha, Adriana and Moreira de Andrade, Jurandyr and Lanchote, Vera Lucia and Bianchi Ximenez, João Paulo},
title = {From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70103}
}
EUVIMED